by Cardiovascular calcification refers to the pathological deposition of calcium phosphate crystals in the blood vessels or heart valves. It is commonly seen in patients with Chronic kidney disease (CKD), diabetes, or atherosclerosis. Cardiovascular calcification increases the risk of heart attacks and strokes. Medical imaging technologies like CT scans and X-rays are used to detect and monitor cardiovascular calcification. Drugs like bisphosphonates and calcimimetics are used to treat and prevent further progression of cardiovascular calcification. The global cardiovascular calcification market comprises drugs, medical imaging systems, lab testing equipment and other accessories required for the diagnosis and treatment of cardiovascular calcification.The market is driven by the rising geriatric population, increasing prevalence of CKD and growth in medical imaging technologies.
The Global Cardiovascular Calcificatin Market is estimated to be valued at US$ 2.3 Billion in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024-2030.
Key Takeaways
Key players: Key players operating in the cardiovascular calcification market are General Electric, Siemens, Philips, Canon, Hitachi and Fujifilm.
Growing demand: The increasing cases of CKD, diabetes and cardiovascular diseases have led to rising demand for cardiovascular calcification diagnosis and treatment. Early detection of cardiovascular calcification helps reduce mortality rates.
Global expansion: Major market players are expanding their geographical presence into emerging markets of Asia Pacific, Latin America and Middle East & Africa to tap the growth opportunities in these regions. Companies are also investing in development of novel drugs and imaging technologies.
Market Trends
The use of artificial intelligence and machine learning is gaining traction in the cardiovascular calcification market. AI-powered imaging and analysis tools help detect even subtle signs of calcification and quantify calcification burden more accurately. This aids in early diagnosis and monitoring of disease progression. Development of new drug formulations that can selectively inhibit abnormal bone mineralization without affecting normal bone health can also drive the market growth.
Porter’s Analysis
Threat of new entrants: Low due to cost intensive R&D and clinical trials needed. Established players hold majority market share.
Bargaining power of buyers: Moderate as healthcare facilities bargain for discounts. Significant treatment volume increases buyer bargaining power.
Bargaining power of suppliers: Moderate to high as suppliers have capability to manufacture cardiac medications and niche products in small volumes.
Threat of new substitutes: Low as no close substitutes currently exist for cardiac calcification treatment. Robust pipeline of novel therapies may increase substitution threats over the long term.
Competitive rivalry: Intense as established players compete to gain market share. Companies focus on drug efficacy, safety, pricing and branding to differentiate products.
North America accounts for the largest share of the cardiovascular calcification market primarily due to increased prevalence of cardiovascular diseases, growing obese and geriatric population, and availability of advanced healthcare infrastructure and reimbursement systems. The rising cases of diabetes and lifestyle changes leading to obesity and high cholesterol also contribute to North America’s large market share.
Asia Pacific is poised to grow at the fastest rate during the forecast period. Factors such as rising healthcare expenditure, increasing demand for quality medical care due to growing diabetes and heart disease burden, rising disposable income, and growth of medical tourism industry in Asia Pacific countries are driving the market. Governments are implementing initiatives to enhance healthcare access which along with rapid economic development will contribute to the cardiovascular calcification market growth in Asia Pacific.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
